NVRO Stock Recent News
NVRO LATEST HEADLINES
Nevro's (NVRO) latest announcement of a positive coverage update from Carelon Healthcare for PDN treatment is likely to serve a wider patient pool.
Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.
Nevro Corp.'s stock NVRO, +5.27% rose by 0.3% in premarket trades on Tuesday after the Redwood City, Calif.-based medical device maker said it would reduce its work force by 5% or 63 people.
REDWOOD CITY, Calif. , Jan. 4, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that members of its management team will participate in the 42nd Annual J.P.
Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge.
Nevro's (NVRO) latest acquisition is likely to bring long-term pain relief to people suffering from chronic low back pain associated with the SI joint.
Nevro (NVRO) reported earnings 30 days ago. What's next for the stock?
Nevro Corp. shares have significantly underperformed, selling 57% lower than in 2021. The company's top-line momentum continues, but it faces economic challenges and lacks value creation for shareholders. As a positive, NVRO's Q2 FY'23 showed significant growth in painful diabetic neuropathy revenues.
Nevro's (NVRO) HFX Connect system is expected to treat individual patients per their requirements with 35 pre-programmed customizable plans.
Nevro said it expects third-quarter revenue to fall between 4% to 6% year over year. The company is reorganizing its sales force.